Literature DB >> 25380845

In vitro immunological effects of blocking CCR5 on T cells.

Jing Yuan1, Han-Yun Ren, Yong-Jin Shi, Wei Liu.   

Abstract

Blockade of CC chemokine receptor 5 (CCR5) by maraviroc may induce immunological changes independent of its antiviral effects and may have immunoregulation properties. This study was designed to determine the effects of blocking CCR5 on human activated T cells in vitro and investigate the potential immunological mechanisms. Human CD3+ T cells were purified from peripheral blood mononuclear cells and then activated by cytokines. We tested the surface expressions and relative messenger RNA (mRNA) levels of CCR2, CCR5, CCR6, CCR7, and CXCR3, chemotaxis toward their cognate ligands, internalization of chemokine receptors, and production of cytokines. In conclusion, blocking CCR5 by maraviroc not only can block CCR5 and CCR2 internalization processes induced by CCL5 and CCL2, but also inhibit T cell chemotactic activities toward their cognate ligands, respectively. Moreover, blocking CCR5 with maraviroc at high doses tends to decrease the production of TNF-α and IFN-γ. In addition, there might be a form of cross talk between CCR5 and CCR2, and this may offer a novel immunological effect for blockade of CCR5.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25380845     DOI: 10.1007/s10753-014-0052-6

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  23 in total

1.  Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning.

Authors:  Christian A Wysocki; Susan B Burkett; Angela Panoskaltsis-Mortari; Suzanne L Kirby; Andrew D Luster; Karen McKinnon; Bruce R Blazar; Jonathan S Serody
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

2.  T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.

Authors:  Ildefonso Pulido; Kawthar Machmach; María C Romero-Sánchez; Miguel Genebat; Gema Mendez-Lagares; Ezequiel Ruiz-Mateos; Manuel Leal
Journal:  J Infect       Date:  2011-12-29       Impact factor: 6.072

Review 3.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

4.  Allogeneic compact bone-derived mesenchymal stem cell transplantation increases survival of mice exposed to lethal total body irradiation: a potential immunological mechanism.

Authors:  Shukai Qiao; Hanyun Ren; Yongjin Shi; Wei Liu
Journal:  Chin Med J (Engl)       Date:  2014       Impact factor: 2.628

5.  Chemokines and their receptors in human renal allotransplantation.

Authors:  Denise J Lo; Tim A Weaver; David E Kleiner; Roslyn B Mannon; Lynn M Jacobson; Bryan N Becker; S John Swanson; Douglas A Hale; Allan D Kirk
Journal:  Transplantation       Date:  2011-01-15       Impact factor: 4.939

6.  Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2.

Authors:  Graeme O'Boyle; John G Brain; John A Kirby; Simi Ali
Journal:  Mol Immunol       Date:  2006-11-01       Impact factor: 4.407

7.  The role of chemokine receptors in acute lung allograft rejection.

Authors:  S Geleff; D Draganovici; P Jaksch; S Segerer
Journal:  Eur Respir J       Date:  2009-07-16       Impact factor: 16.671

8.  Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.

Authors:  Nicholas Funderburg; Magdalena Kalinowska; James Eason; James Goodrich; Jayvant Heera; Howard Mayer; Natasa Rajicic; Hernan Valdez; Michael M Lederman
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

Review 9.  The biology of CCR5 and CXCR4.

Authors:  Ghalib Alkhatib
Journal:  Curr Opin HIV AIDS       Date:  2009-03       Impact factor: 4.283

Review 10.  Clinical use of CCR5 inhibitors in HIV and beyond.

Authors:  Bruce L Gilliam; David J Riedel; Robert R Redfield
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

View more
  6 in total

1.  Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model.

Authors:  Jing Yuan; Han-yun Ren; Yong-jin Shi; Wei Liu
Journal:  Inflamm Res       Date:  2015-01-04       Impact factor: 4.575

2.  The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.

Authors:  María Rosa López-Huertas; Laura Jiménez-Tormo; Nadia Madrid-Elena; Carolina Gutiérrez; Sara Rodríguez-Mora; Mayte Coiras; José Alcamí; Santiago Moreno
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

3.  MEKK1 Regulates Chemokine Expression in Mammary Fibroblasts: Implications for the Breast Tumor Microenvironment.

Authors:  Saverio Gentile; Najmeh Eskandari; Michael A Rieger; Bruce D Cuevas
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

Review 4.  C-C chemokine receptor 5 and acute graft-versus-host disease.

Authors:  Jing Yuan; Han-Yun Ren
Journal:  Immun Inflamm Dis       Date:  2022-09

Review 5.  Maraviroc: a review of its use in HIV infection and beyond.

Authors:  Shawna M Woollard; Georgette D Kanmogne
Journal:  Drug Des Devel Ther       Date:  2015-10-01       Impact factor: 4.162

6.  CCR5-Δ32 polymorphism: a possible protective factor for post-stroke depressive symptoms.

Authors:  Oren Tene; Hen Hallevi; Jeremy Molad; Saly Usher; Estelle Seyman; Natan M Bornstein; Shani Shenhar-Tsarfaty; Einor Ben Assayag
Journal:  J Psychiatry Neurosci       Date:  2021-07-22       Impact factor: 6.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.